Showing results (201-210 of 412) with videos related to
Sort By:
Pageof 42
British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.Frontiers in Immunology|January 24, 2022
Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1Monika Avbelj, Iva Hafner-Bratkovič, Duško Lainšček, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)Scott J Rodig, Jeremy S Abramson, Geraldine S Pinkus, et al.British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.Blood|February 24, 2016
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemiaAldo M Roccaro, Antonio Sacco, Jiantao Shi, et al.Seminars in Oncology|April 30, 2003
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerationsSteven P Treon, Abigail Kelliher, Beverly Keele, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.Pageof 42